VSGN

[stout7735]

Early termination of one trial yesterday  led to crash over 50%...Other CHF phase 111 trial continues to look positive...Despite VSGN weak finances to survive into 2006,A G Edwards likes it at $5...Downturn may be overdone...When begins to  trend up,may be good short term investment...Sell at $2.79???

[stout7735]

Today is the day to buy...Trending up...Good short term profit potential...

[stout7735]

It is days like this i feel like an idiot,down 14%...Crashed through all support and stops...May go low enough to become a candidate for 3stocksonfire someday...At least most of  the shorts took their profits and left...I will watch it now to look for a SUSTAINED rally...The cliinicians feel  positive toward the product being tested now...

[setravis]

This one looks good for a play now.
May want to close this gap. Great volume and moving nice.

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
28.92%above 13-day EMA
-0.41%below 50-day EMA
RS Rating: 2 

Fundamentals
Key Data:
Market Cap (M): $190.55 
Last Analyst Rating: Buy

[stocks2watch2]

Vasogen`s Phase III SIMPADICO Results to be Presented at Late-Breaking Session of the 55th Annual Scientific Session of the American College of Cardiology

February 01, 2006 06:01:01 (ET)


TORONTO, Feb 01, 2006 /PRNewswire-FirstCall via COMTEX/ -- Vasogen Inc. (VSGN, Trade), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that the pivotal phase III SIMPADICO trial in peripheral arterial disease (PAD) has been accepted for presentation at a Late- Breaking Clinical Trial session of the 55th Annual Scientific Session of the American College of Cardiology (ACC). The ACC meeting, which is being held in Atlanta from March 11 to 14, 2006, attracts approximately 20,000 cardiovascular professionals from the United States, Canada, and the rest of the world.

The initial results of the SIMPADICO trial of the Company's Celacade(TM) technology in PAD will be presented by Dr. Jeffrey Olin, on Sunday, March 12, at 2:45 p.m. E.T., at the Georgia World Congress Center. The Company will issue a press release providing details on the trial results at the time of Dr. Olin's presentation. Dr. Olin is Professor of Medicine at the Mount Sinai School of Medicine, Director of Vascular Medicine at The Zena and Michael A. Wiener Cardiovascular Institute in New York, and Principal Investigator and Chairman of the Steering Committee for the SIMPADICO trial.

"The opportunity to present the SIMPADICO trial results at a Late-Breaking Clinical Trial session of the American College of Cardiology recognizes both the quality of this pivotal study and the growing need for new approaches to treat patients with peripheral arterial disease," stated Dr. Jay H. Kleiman, Chief Medical Officer and Head of Cardiovascular Development of Vasogen Inc. "We now look forward to the analysis and interpretation of the SIMPADICO data and to the presentation of the initial findings from this study at the ACC meeting."

The ACC selects presentations for Late-Breaking Clinical Trial sessions based on the potential of the study to affect clinical practice, the impact and novelty of the research, the rigor of the design/methods, the major clinical endpoints, and the quality of the statistical plan.

The SIMPADICO trial was designed to further investigate the use of Vasogen's Celacade technology to improve intermittent claudication, a debilitating symptom associated with PAD. SIMPADICO is a double-blind, placebo-controlled trial that enrolled 550 patients at 50 sites in the United States and Canada. The primary endpoint of SIMPADICO is the change in maximum walking distance from baseline to 26 weeks assessed on a constant speed treadmill with increasing grade. The study was also designed to investigate the impact of Celacade on additional endpoints, including PAD and cardiovascular-related events, and quality of life.

Peripheral arterial disease is a serious condition due to impaired blood flow to the lower extremities resulting from atherosclerosis. The disease often leads to reduced mobility and a marked impairment in the ability to undertake basic activities of daily independent living. It is estimated that in the United States alone, PAD affects approximately nine million people, with related healthcare costs exceeding $10 billion annually. The condition is associated with a high level of morbidity, and an estimated 30% of patients diagnosed with PAD will die within five years. Patients also have a six-fold increase in risk of death from cardiovascular disease, and often experience the symptom of intermittent claudication (leg pain on walking). Currently, there are limited effective pharmacological therapies available for the treatment of intermittent claudication, and there is a need for a more effective treatment option.

[setravis]

Nice move and volume today !
Today a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure....

The last two candlesticks formed a Bullish Kicking Pattern . This is a bullish reversal pattern that marks a potential change in trend. Though it is highly reliable confirmation is still recommended....

The last three candlesticks formed a Bullish Morning Star Pattern . This is a bullish reversal pattern that marks a potential change in trend. Though it is highly reliable confirmation is still recommended....


Support @ $2.74...2.27...1.92
Resistance @ $2.98...5.18...5.28


Technicals
MACD is Bullish
Stochastic is Bearish....but turning up
Percentage Gainer

Last Price Quote is:
22.84%above 13-day EMA
24.81%above 50-day EMA
RS Rating: 19 

Fundamentals
Key Data:
Market Cap (M): $195.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

[stocks2watch2]

Sold 1/3 @ 3.06.If it holds 3 I'll hold the rest.
Bid-3.03
Ask-3.05

[setravis]

I never sell until the chart does the talking.....
Great volume...
Volume: 2,693,107
Avg Volume (3m): 481,722


Technicals
Percentage Gainer

Last Price Quote is:
36.19%above 13-day EMA
41.51%above 50-day EMA
RS Rating: 74 

Fundamentals
Key Data:
Market Cap (M): $195.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

[stocks2watch2]

I never sell until the chart does the talking.....

And I like to sell some into the run, to buy a little insurance . Now averaged down to  2.25  Whatever works for you as long as your making some money. I'm having a hell of a year so far.

[setravis]

I never sell until the chart does the talking.....

And I like to sell some into the run, to buy a little insurance . Now averaged down to  2.25  Whatever works for you as long as your making some money. I'm having a hell of a year so far.

I hear you  stocks2watch2 ! What ever is working for you, "Do it to it" !! 
Glad to hear you bringing in the profits.....Keep it rolling my friend...
Applaud to you.....

[stocks2watch2]

We all know your the chart guru . I'm gonna take another 1/3 of this one today. Good Luck to you. Keep up the good work. If you get the chance take a look at the charts on IMGN,SPAB.

[stocks2watch2]

Out@ 3.43. Good Luck if your still holding.

[Terliso]

Bottom fishing!!

[akclide]

just put a order in for [email protected], let's see what happens

[Terliso]

The close is not so bad huh, acklide?

I don't expect VSGN to close that gap soon, but i'm hoping the bulls to penetrate the 0.74 tomorrow morning

Good luck!